Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.71 |
| ▸ | RAB9A | P51151 | 6/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.68 |
| ▸ | MEN1 | O00255 | 5/20 | 0.68 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.68 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673898 | 0.89 | KCNK3 (0.61) | NPC1RAB9AHPGDKMT2AMEN1 | |
| SCHEMBL18410447 | 0.83 | HDAC1 (0.67) | NPC1RAB9AHPGDKMT2AMEN1 | |
| SCHEMBL23447715 | 0.83 | NPC1 (1.00) | NPC1RAB9AHPGDKMT2AMEN1 | |
| SCHEMBL30799158 | 0.83 | KMT2A (0.70) | NPC1RAB9AHPGDKMT2AMEN1 | |
| SCHEMBL19156982 | 0.81 | KCNK3 (0.91) | NPC1RAB9AHPGDKMT2AMEN1 | |
| SCHEMBL29817846 | 0.81 | NPC1 (0.71) | NPC1RAB9AHPGDKMT2AMEN1 | |
| SCHEMBL4258383 | 0.81 | NPC1 (0.71) | NPC1RAB9AHPGDKMT2AMEN1 | |
| SCHEMBL16431098 | 0.81 | PTGS1 (0.63) | KMT2AMEN1KCNK3KCNK9SMN1; SMN2 | |
| SCHEMBL1353546 | 0.81 | NPC1 (0.71) | NPC1RAB9AHPGDKMT2AMEN1 | |
| SCHEMBL7241176 | 0.81 | NPC1 (0.71) | NPC1RAB9AHPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501513-B1 | COMPOSITIONS AND METHODS FOR COMBATING LOWER URINARY TRACT DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONISTS | VERSI GROUP LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8476280-B2 | Modulate contraction, relaxation of muscles | VERSI GROUP, LLC (US) | 2013-07-02 | — | — | US | disclosed |
| EP-1501513-A2 | COMPOSITIONS AND METHODS FOR COMBATING LOWER URINARY TRACT DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONISTS | Ardent Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040002503-A1 | Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists | VERSI GROUP, LLC | 2004-01-01 | — | — | US | disclosed |
| WO-2003094853-A2 | COMPOSITIONS AND METHODS FOR COMBATING LOWER URINARY TRACT DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONISTS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002503-A1 | Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists | OPRD1, OPRK1, OPRM1 | NPC1 3861/4885RAB9A 3408/4885HPGD 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.